Clinical Trials
10 trialsNCT01231412 2026-04-30
Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant
Fred Hutchinson Cancer Center
Phase 3 Completed
NCT02512497 2025-09-19
Romidepsin Maintenance After Allogeneic Stem Cell Transplantation
Ohio State University Comprehensive Cancer Center
Phase 1 Completed
NCT04312841 2025-02-28
Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab
Ohio State University Comprehensive Cancer Center
Phase 2 Completed
NCT03989466 2024-10-10
Itacitinib and Alemtuzumab in Treating Patients With T-Cell Prolymphocytic Leukemia
M.D. Anderson Cancer Center
Phase 1 Completed
NCT01186640 2022-01-05
Combined Immunochemotherapy in Patients With T-Prolymphocytic Leukemia (T-PLL)
German CLL Study Group
Phase 2 Completed
NCT01094860 2020-02-11
Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Nelarabine in Patients With Relapsed/Refractory Lymphoid Malignancies
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00005803 2020-01-29
Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma
Fred Hutchinson Cancer Center
Phase 1/2 Completed
NCT01251575 2019-12-09
Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant
Fred Hutchinson Cancer Center
Phase 2 Completed
NCT01008462 2019-06-11
Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia
Fred Hutchinson Cancer Center
Phase 2 Completed
NCT00060424 2017-12-08
Fludarabine Phosphate and Total-Body Irradiation Before Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia
Fred Hutchinson Cancer Center
Phase 2 Completed